We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Nektar Inks $1.85B Bristol-Myers Cancer Drug Collaboration

Law360 (February 14, 2018, 2:13 PM EST) -- Nektar Therapeutics has inked a $1.85 billion cash-and-stock deal to jointly develop and manage its cancer-fighting, immuno-stimulatory therapy in combination with two Bristol-Myers Squibb cancer treatments, the companies said Wednesday....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.